Beckley Psytech Acquires Eleusis Therapeutics Limited

Beckley Waves (via NueCo Holdings PBC) Acquires Nue Life Health

October 26, 2023

Healthcare Services

Beckley Waves, a venture studio focused on building companies in the psychedelic ecosystem, has acquired the assets of Nue Life Health Inc. through a newly launched portfolio company, NueCo Holdings PBC. The acquisition will allow Beckley Waves to scale Nue Life's at-home ketamine-assisted therapy platform and expand access to underserved patients across the United States.

Blue Water Ventures International Acquires Psycheceutical, Inc.

January 20, 2022

Biotechnology

Blue Water Ventures International, Inc. (BWVI) has completed a merger to acquire Psycheceutical, Inc., making the biotech a wholly-owned subsidiary. BWVI — a publicly-listed company — will pivot its business to focus on psychedelic drug development and intends to provide near-term capital as Psycheceutical advances its delivery technologies toward initial clinical trials.

EQT Private Equity to Acquire Zeus Company Inc

December 18, 2023

Medical Devices

EQT Private Equity (via its EQT X fund) has entered into an agreement to acquire Zeus Company, Inc., a global leader in advanced polymer components for medical devices, from the Tourville family. EQT plans to support Zeus with investments in production capacity, R&D, and operational improvements to accelerate growth in minimally invasive medical device markets.

Excelitas Technologies Acquires Phoseon Technology

February 15, 2023

Manufacturing

Excelitas Technologies Corp. completed the acquisition of Phoseon Technology, Inc. on February 15, 2023, adding Phoseon's LED-based UV curing and scientific illumination capabilities to its commercial business unit. Phoseon will continue to operate from its Hillsboro, Oregon headquarters and the deal expands Excelitas' product portfolio and R&D cooperation in UV LED solutions across industrial, medical device, electronics and life-sciences end markets.

Eilean Therapeutics Acquires Ness Therapeutics

March 4, 2024

Biotechnology

Eilean Therapeutics LLC acquired Ness Therapeutics Inc in an all-equity transaction to obtain Ness’s preclinical PTPN2 inhibitor program. The acquisition expands Eilean’s immuno-oncology pipeline and capabilities in small-molecule inhibitors targeting resistance mechanisms in hematologic and solid malignancies.

Concentra Biosciences (Tang Capital) to Acquire Theseus Pharmaceuticals

December 22, 2023

Biotechnology

Concentra Biosciences, a vehicle controlled by Tang Capital Partners, has entered into a definitive merger agreement to acquire clinical-stage biotech Theseus Pharmaceuticals for $3.90–$4.05 per share in cash plus a contingent value right tied to future program licensing/disposition proceeds. The transaction will be effected by a tender offer and is expected to close in February 2024, subject to customary conditions and the availability of required cash at closing.